
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics is expected to experience long-term commercial success due to its best-in-class technology in BPH treatment, evidence of management execution, and potential for continued uptake of its HYDROS system across the U.S. and internationally. While competition and pricing pressures may pose risks to its growth, the company is well-positioned in the market and has potential for significant sales contribution in the future. Investors may benefit from purchasing PROCEPT BioRobotics shares due to its strong potential for double-digit sales growth over the next decade in the large and underpenetrated BPH surgical market.
Bears say
PROCEPT BioRobotics is facing significant challenges, including a disappointing quarter and lower revenue guidance, as well as uncertainties around its commercial initiatives and competition in the market. While there are potential positives, such as strong procedure growth and record domestic capital placements, the negative factors and uncertainties lead to a negative outlook for the stock. Additionally, the company's stock is currently bidding down significantly in after-hours trading.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares